American Diabetes Association

Web-Based Program Reduces Risk of Diabetes in Women

June 17, 2020

Women with recent gestational diabetes who use the intervention see less retention of weight than those who do not use the intervention.

Oral Semaglutide Effective Regardless of Background T2D Therapy Use

June 17, 2020

An analysis of data from 5 PIONEER trials is shedding new light on the impact of oral semaglutide based on background glucose-lowering therapy.

Empagliflozin Decreases Risk of Heart Failure Hospitalization

June 17, 2020

The drug also reduced the risk of myocardial infarction and stroke.

Testosterone, Lifestyle Program Reduce Risk of Type 2 Diabetes in Men

June 17, 2020

Taking testosterone while enrolled in a lifestyle program reduces glucose levels and risk of type 2 diabetes.

State of Diabetes Care in 2020 with Robert Busch, MD

June 17, 2020

Discussing how advances in care and therapeutic agents have impacted the management of diabetes in 2020.

Todd Hobbs, MD: Positive Results of Once-Weekly Insulin Icodec Vs Glargine

June 17, 2020

Todd Hobbs, MD, breaks down research presented at ADA 2020.

Serge Jabbour, MD: Incidence and Impact of Herpes Zoster in T2DM Patients

June 16, 2020

Discussing an analysis of retrospective claims data to examine the incidence of herpes zoster in patients with T2DM and how it impacts their diabetes.

Ertugliflozin Noninferior to Placebo for Cardiovascular Safety in VERTIS-CV

June 16, 2020

Lead investigator of VERTIS-CV discusses results of the phase 3 trial examining ertugliflozin's impact on cardiovascular health.

Long-Term Lifestyle Program, Metformin Both Reduce Risk of Type 2 Diabetes

June 16, 2020

The prevention of type 2 diabetes is possible and has important clinical benefits.

Youth, Young Adults Have Worse Glycemic Control Than in the Past

June 16, 2020

Not all youth and young adults with diabetes are directly benefiting from the increased availability of diabetes technology, newer therapies, and the use of more aggressive glycemic targets.